Osteologix Receives Positive Decision To Grant A Patent For Key Osteoporosis Drug Patent In Japan

Osteologix, Inc. (OTCBB:OLGX) announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for Application Number 2006-504379: “Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts”. The patent claims cover the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the Company’s lead osteoporosis drug candidate. The Company expects the patent will issue by the end of 2009.

source : www.medicalnewstoday.com

Related News:

• UCLA School Of Dentistry To Build New Cancer Research Facility
• Elan revises J&J deal to appease Biogen
• MUHC/McGill researchers to WHO: Time to revise tuberculosis treatment guidelines
• Eli Lilly to cut 5,500 jobs by 2011
• New hospital, possible medical school attracting doctors to Merced
• Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG
• Three SE distinguished alumni to be honored at homecoming
• Geriatric expert to speak at fundraiser
• JHSPH To Lead Extremity Trauma Clinical Research Consortium
• AOBO Launches New OTC Product To Treat Throat Inflammation